- DKK13.54bn
- DKK11.39bn
- DKK6.24bn
US CDC advisers recommend lowering the age for RSV shots to 50-59 years (updated)
Brief: Bavarian Nordic’S Chikungunya Vaccine Receives Recommendation From U.S. CDC’S Advisory Committee On Immunization Practices
European healthcare drops as Trump says tariffs on sector coming soon
European healthcare drops as Trump says tariffs on sector coming soon
European pharma stocks fall ahead of Trump's 'Liberation Day'
European shares recover ahead of US tariffs
US FDA approves freeze-dried version of Bavarian Nordic's mpox, smallpox vaccine
Brief: Bavarian Nordic Receives U.S. FDA Approval Of Freeze-Dried Smallpox And Mpox Vaccine
Factbox: Widely used drugs on US imports list from Europe
Brief: Bavarian Nordic Announces UK Acceptance of Chikungunya Vaccine
Brief: Bavarian Nordic Outlook FY Revenue DKK 5.7-6.7 Bln
Brief: Bavarian Nordic Receives Marketing Authorization In Europe For Chikungunya Vaccine For Persons Aged 12 And Older
Brief: Bavarian Nordic Partners With Biological E To Expand Global Access To Chikungunya Vaccine
Bavarian Nordic rises on FDA approval for chikungunya vaccine
Brief: Bavarian Nordic Receives U.S. FDA Approval Of Chikungunya Vaccine For Persons Aged 12 And Older
Factbox: Pending US vaccine decisions as Kennedy takes top health job
Bavarian Nordic drops 10% after earnings guidance comes short
Brief: Bavarian Nordic FY EBITDA DKK 1,603 Million Vs. IBES Estimate DKK 1,488 Million
Brief: Bavarian Nordic Says For 2025, Co Expects Revenue Of DKK 5,700 - 6,700 Mln & An EBITDA-Margin Of 26-30%.